文献速递脊柱关节炎

培塞利珠单抗治疗中轴型脊柱关节炎的4年疗效、安全性与患者报告结局

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

RAPID-axSpA是一项3期随机对照试验,评估培塞利珠单抗在活动性中轴型脊柱关节炎(axSpA)患者中持续治疗4年的长期安全性与疗效,纳入AS和nr-axSpA两个亚型。结果显示至第204周,ASAS20、ASAS40、ASDAS inactive disease等各项临床与患者报告结局均持续改善,未发现新的安全信号,无死亡报告。

要点

  • 至第204周,ASAS20(NRI)为54.1%,ASAS40(NRI)为44.0%,ASDAS inactive disease(LOCF)为32.1%。
  • 安全性集(n=315)中,不良事件发生率292.8/100患者年,严重不良事件10.4/100患者年,无死亡报告。
  • AS与nr-axSpA两个亚型在全部结局上均观察到持续改善至第204周。

核心结论

  • 培塞利珠单抗治疗活动性axSpA(含AS与nr-axSpA)至第204周,临床与患者报告结局的改善持续维持,未发现新的安全信号,无死亡报告。

研究设计与样本

  • RAPID-axSpA为3期随机试验,双盲安慰剂对照至第24周,剂量盲至第48周,开放标签至第204周。
  • 安全性集n=315。

主要发现

  • 第204周时65%患者仍在研究中(AS 67%,nr-axSpA 63%)。
  • 第204周整体axSpA:ASAS20为54.1%(NRI)、83.7%(OC);ASAS40为44.0%(NRI)、68.1%(OC)。
  • 第204周整体axSpA:ASDAS inactive disease为32.1%(LOCF)、31.4%(OC)。
  • AS与nr-axSpA在全部结局上均观察到持续改善至第204周。
  • 安全性集(n=315)中,不良事件292.8/100患者年,严重不良事件10.4/100患者年,无死亡报告。

关键数值与推荐

  • ASAS20(第204周,整体axSpA):54.1%(NRI)、83.7%(OC)。
  • ASAS40(第204周,整体axSpA):44.0%(NRI)、68.1%(OC)。
  • ASDAS inactive disease(第204周,整体axSpA):32.1%(LOCF)、31.4%(OC)。
  • 安全性集(n=315):不良事件292.8/100患者年,严重不良事件10.4/100患者年,无死亡报告。

临床怎么用

  • 对于符合ASAS标准的活动性axSpA(含AS与nr-axSpA),培塞利珠单抗持续治疗至4年可维持临床与患者报告结局的改善。
  • 长期治疗中不良事件与严重不良事件发生率需结合安全性集数据(292.8与10.4/100患者年)进行监测。

局限性

  • 第48周后为开放标签设计,缺乏长期对照。
  • 第204周数据同时采用NRI、OC与LOCF等不同缺失处理方法报告,解读需注意方法差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim was to assess the long-term safety and efficacy of certolizumab pegol over 4 years of continuous treatment in patients with axial spondyloarthritis (axSpA), including both AS and non-radiographic (nr-) axSpA. METHODS: RAPID-axSpA was a phase 3 randomized trial, double blind and placebo controlled to week 24, dose blind to week 48 and open label to week 204. Patients had a clinical diagnosis of axSpA, meeting Assessment of SpondyloArthritis international Society (ASAS) criteria, and had active disease. The assessed outcomes included ASAS20, ASAS40, AS DAS (ASDAS), BASDAI, BASFI and BASMI scores, along with selected measures of remission. Further patient-reported outcomes, peripheral arthritis, enthesitis, uveitis and quality-of-life measures are also reported. RESULTS: Two hundred and eighteen of 325 patients randomized (AS: 121; nr-axSpA: 97) received certolizumab pegol from week 0. Of these, 65% remained in the study at week 204 (AS: 67%; nr-axSpA: 63%). Across all outcomes, for AS and nr-axSpA, sustained improvements were observed to week 204 [week 204 overall axSpA: ASAS20: 54.1% (non-responder imputation); 83.7% (observed case, OC); ASAS40: 44.0% (non-responder imputation); 68.1% (OC); ASDAS inactive disease: 32.1% (last observation carried forward); 31.4% (OC)]. In the safety set (n = 315), there were 292.8 adverse events and 10.4 serious adverse events per 100 patient-years. No deaths were reported. CONCLUSION: In the first study to evaluate the efficacy of an anti-TNF across both axSpA subpopulations, improvements in clinical and patient-reported outcomes at 24 and 96 weeks were sustained through 4 years of treatment, with no new safety signals. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT01087762.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. van der Heijde D, Dougados M, Landewé R, et al. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (Oxford). 2017. PMID: 28498975. doi:10.1093/rheumatology/kex174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。